Dynamic Advisor Solutions LLC Buys 3,691 Shares of Astrazeneca Plc $AZN

Dynamic Advisor Solutions LLC lifted its stake in shares of Astrazeneca Plc (NYSE:AZN) by 25.4% during the fourth quarter, Holdings Channel reports. The fund owned 18,196 shares of the company’s stock after buying an additional 3,691 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in Astrazeneca were worth $1,673,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of AZN. Triumph Capital Management acquired a new stake in shares of Astrazeneca in the 3rd quarter worth about $25,000. Rakuten Investment Management Inc. bought a new position in Astrazeneca in the 3rd quarter valued at about $31,000. JPL Wealth Management LLC acquired a new position in Astrazeneca during the 3rd quarter valued at about $35,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in Astrazeneca by 144.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock valued at $36,000 after purchasing an additional 275 shares during the last quarter. Finally, Abound Wealth Management increased its holdings in Astrazeneca by 1,767.9% during the 3rd quarter. Abound Wealth Management now owns 523 shares of the company’s stock worth $40,000 after purchasing an additional 495 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on AZN. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Barclays reaffirmed an “overweight” rating on shares of Astrazeneca in a research report on Tuesday, January 6th. Morgan Stanley reissued an “overweight” rating and issued a $103.00 price target on shares of Astrazeneca in a research report on Wednesday, December 3rd. Guggenheim restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, December 3rd. Finally, Citigroup initiated coverage on shares of Astrazeneca in a report on Tuesday, January 27th. They set a “buy” rating on the stock. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $95.75.

Astrazeneca Price Performance

NYSE:AZN opened at $185.54 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72. Astrazeneca Plc has a 1 year low of $122.48 and a 1 year high of $212.71. The firm has a market capitalization of $287.75 billion, a price-to-earnings ratio of 31.96, a PEG ratio of 1.39 and a beta of 0.32.

Astrazeneca Dividend Announcement

The company also recently declared a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were paid a dividend of $1.595 per share. The ex-dividend date was Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca’s dividend payout ratio is presently 74.83%.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.